Gennex Laboratories Share Price Partly Paidup

Net claims of non-residents on India rise by US$11 billion during Q3FY25

Sebi eases intraday monitoring rules for index derivatives amid opposition

India's services export earnings up 11.6% on year, services imports fall around 5%

Benchmarks ends with moderate losses; media shares under pressure

India's Current Account Deficit stood at US$11.5 billion or 1.1% of GDP in Q3FY25

Go through the enclosed Announcement

Pursuant to concord entered between DRL and M/s. Forel Labs Private Limited (FLPL) DRL acquired live running US FDA (Food and Drug Administration) complied plant of FLPL located at Plot #58A Road #1 J.N.Pharma City Parawada Visakhapatnam - 531 021 AP India which have capacity of 90 KL and licence to run various API registration for the above manufacturing plant is completed and approved by the SRO Lankelapalem Visakhapatnam.

Pursuant to announcement of Board Meeting dated January 04 2022 we hereby inform you 836165 equity shares equivalent to 6.73% of Deccan Remedies Limited (DRL) acquired from the existing promoters shareholders group and the share funded through internal accruals and in turn the Company will hold 51% equity shares of DRL.Further the Company holds composition of the Board Directors and referring to the above share acquired exercises or controls more than one-half of the total voting power either at its own or together with one or more of its promoters shareholders group. Based on controlling position and voting power in DRL the Company will fall under Sec.2(46) of the Companies Act (CA) 2013 Holding Company definition and DRL shall fall Subsidiary Company Definition u/Sec.2(87) of the CA 2013.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Newspaper Publication on Meeting of the Board of Directors of the Company Scheduled to be held on Tuesday February 14 2023 for the adoption of Unaudited (Standalone & Consolidated) financial results for the Quarter and Nine Months ended December 31 2022. Notice had been published in both Business Standard and Andhra Prabha on February 08 2023.We request you to take the above information on record and acknowledge the receipt of the same.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed herewith Newspaper Publication on Unaudited (Standalone & Consolidated) Financial results for the Quarter and Nine Months ended December 31 2022 announced by the Board of Directors in their meeting held on February 14 2023. Financial results had been published in both Business Standard and Andhra Prabha on February 16 2023.We request you to take the above information on record and acknowledge the receipt of the same.